Establishment Labs (NASDAQ:ESTA) Issues Earnings Results, Beats Expectations By $0.18 EPS

Establishment Labs (NASDAQ:ESTAGet Rating) issued its quarterly earnings data on Monday. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.18, MarketWatch Earnings reports. Establishment Labs had a negative net margin of 32.47% and a negative return on equity of 64.87%. During the same period last year, the company posted ($0.29) EPS. Establishment Labs updated its FY 2022 guidance to EPS.

ESTA stock opened at $50.15 on Tuesday. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -29.33 and a beta of 1.08. Establishment Labs has a 1-year low of $46.93 and a 1-year high of $93.80. The company’s fifty day simple moving average is $67.06. The company has a current ratio of 3.55, a quick ratio of 2.66 and a debt-to-equity ratio of 1.02.

Several research firms recently commented on ESTA. BTIG Research boosted their price target on Establishment Labs from $95.00 to $110.00 and gave the stock a “buy” rating in a research note on Friday, April 22nd. Zacks Investment Research lowered Establishment Labs from a “hold” rating to a “sell” rating in a research report on Friday, March 4th. Cowen lifted their price target on shares of Establishment Labs from $95.00 to $125.00 in a research note on Friday, April 22nd. Cowen increased their price objective on shares of Establishment Labs from $95.00 to $125.00 in a research note on Friday, April 22nd. Finally, The Goldman Sachs Group dropped their target price on shares of Establishment Labs from $78.00 to $67.00 and set a “neutral” rating for the company in a research report on Monday, March 21st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $98.86.

In other Establishment Labs news, major shareholder Jw Asset Management, Llc purchased 10,000 shares of Establishment Labs stock in a transaction dated Monday, February 28th. The shares were bought at an average cost of $59.42 per share, for a total transaction of $594,200.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have acquired 60,000 shares of company stock worth $3,868,100 over the last three months. 13.08% of the stock is owned by corporate insiders.

Several institutional investors have recently made changes to their positions in ESTA. Deutsche Bank AG boosted its position in Establishment Labs by 47.6% during the 4th quarter. Deutsche Bank AG now owns 1,002 shares of the company’s stock valued at $68,000 after purchasing an additional 323 shares during the period. Bank of America Corp DE acquired a new stake in Establishment Labs in the second quarter worth $180,000. Jane Street Group LLC lifted its stake in Establishment Labs by 50.7% in the third quarter. Jane Street Group LLC now owns 4,972 shares of the company’s stock valued at $355,000 after buying an additional 1,672 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Establishment Labs by 147.8% during the third quarter. Bank of New York Mellon Corp now owns 11,073 shares of the company’s stock valued at $793,000 after acquiring an additional 6,604 shares during the period. Finally, California State Teachers Retirement System grew its position in shares of Establishment Labs by 3.3% during the fourth quarter. California State Teachers Retirement System now owns 16,081 shares of the company’s stock worth $1,087,000 after acquiring an additional 513 shares during the last quarter. Institutional investors and hedge funds own 77.79% of the company’s stock.

About Establishment Labs (Get Rating)

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution.

Read More

Earnings History for Establishment Labs (NASDAQ:ESTA)

Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.